| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.0M | — | +71.5% |
| R&D Expense | $43.1M | — | +13.2% |
| SG&A Expense | $18.7M | — | +116.5% |
| Operating Income | -$44.9M | — | -21.9% |
| Net Income | -$46.7M | — | -27.4% |
| EPS (Basic) | -$0.20 | — | -25.0% |
| EPS (Diluted) | -$0.20 | — | -25.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $41.0M | +8.7% | +41.4% |
| Short-term Investments | $58.2M | -41.3% | -74.6% |
| Accounts Receivable | $9.3M | -24.3% | +40.5% |
| Current Assets | $124.5M | -25.7% | -54.8% |
| Total Assets | $128.9M | -25.2% | -54.1% |
| Current Liabilities | $56.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$38.7M | — | +2.5% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $41.6M | — | +88.6% |
| Financing Cash Flow | $512K | — | +1.6% |
| Free Cash Flow | -$38.7M | — | +2.6% |
| +17.2% |
| Total Liabilities | $290.4M | -1.6% | +1.2% |
| Stockholders' Equity | -$161.5M | -31.5% | -2483.7% |